Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1/2 5Phase 1 4Phase 3 2

Status

Terminated 4Completed 4Recruiting 2Withdrawn 1Unknown 1Suspended 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Gastrointestinal 2Thoracic 1

Conditions

Melanoma 4Colorectal Neoplasms 2Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Completed × encorafenib × Clear all
NCT01436656 2024-10-28

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Pfizer

Phase 1 Completed
107 enrolled 49 charts
DermatologicGastrointestinal

Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

NCT03864042 2024-09-27

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Pfizer

Phase 1 Completed
56 enrolled 158 charts
Dermatologic

Melanoma

NCT05003622 2024-06-24

OCEANI

Pierre Fabre Medicament

Phase 1 Completed
3 enrolled 26 charts
Dermatologic

Melanoma

NCT02857270 2022-11-22

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Eli Lilly and Company

Phase 1 Completed
210 enrolled
DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡